More thyroid cancers were detected soon after starting a GLP-1 receptor agonist than other diabetes drugs, a secondary ...

Sulfonylureas close these channels and restore insulin release, and have been successfully used to replace insulin treatment for patients with Kir6.2 mutations. Now, Hattersley et al. describe the ...

When GLP-1 receptor agonist users were compared with adults who used sulfonylureas, GLP-1 receptor agonists were associated with higher risk for thyroid cancer (HR = 1.8; 95% CI, 1.28-2.52).

The absolute risk for thyroid cancer is low among patients receiving GLP-1 RA therapy, but risk is elevated in the first year of treatment.

HealthDay News — For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP ... and compared them to patients initiating sulfonylureas, dipeptidyl peptidase 4 (DPP4 ...

The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, according to a ...

With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...

Adults with type 2 diabetes using a GLP-1 drug have a similar risk for thyroid cancer as those using other diabetes drugs, though increased thyroid cancer risk was observed in the first year after GLP ...